Related Experiment Video
Updated: Jan 5, 2026
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
Cost-comparison analysis of a multiplatform tumour profiling service to guide advanced cancer treatment
Gilbert Spizzo1,2, Uwe Siebert3, Guenther Gastl2
1Department of Internal Medicine, Oncologic Day Hospital, Bressanone Hospital (SABES-ASDAA), Bressanone-Brixen, Italy.
Background:
Tumor profiling is increasingly used in advanced cancer patients to define treatment options, especially in refractory cases where no standard treatment is available. Caris Molecular Intelligence (CMI) is a multiplatform tumor profiling service that is comprehensive of next-generation sequencing (NGS) of DNA and RNA, immunohistochemistry (IHC) and in situ hybridisation (FISH). The aim of this study is to compare costs of CMI-guided treatment with prior or planned treatment options in correlation with outcome results.
Methods:
Retrospective data from five clinical trials were collected to define the treatment decision prior to the receipt of the CMI report (n = 137 patients). A systematic review of treatment data from 11 clinical studies of CMI (n = 385 patients) allowed a comparison of planned vs actual (n = 137) and prior vs actual (n = 229) treatment costs.
Results:
Treatment plan was changed in 88% of CMI-profiled cases. The actual CMI guided treatment cost per cycle was £995 in 385 treated patients. Planned treatment costs were comparable to actual treatment costs (£979 vs £945; p = 0.7123) and prior treatment costs were not significantly different to profiling-guided treatments (£892 vs £850; p = 0.631).
Conclusions:
Caris Molecular Intelligence guided treatment cost per cycle was in the range of prior or planned treatment cost/cycle. Due to beneficial overall survival the additional cost of performing CMI's multiplatform testing to the treatment costs seems to be cost-effective.
Insights
Caris Molecular Intelligence (CMI) tumor profiling is cost-effective for advanced cancer patients, with CMI-guided treatment costs comparable to standard options. This comprehensive profiling leads to improved survival outcomes, justifying its use.
Area of Science:
- Oncology
- Genomics
- Health Economics
Background:
- Tumor profiling is crucial for advanced cancer patients, especially those with refractory disease lacking standard treatments.
- Caris Molecular Intelligence (CMI) offers comprehensive multiplatform tumor profiling, including next-generation sequencing (NGS), immunohistochemistry (IHC), and in situ hybridization (FISH).
Purpose of the Study:
- To compare the costs of Caris Molecular Intelligence (CMI)-guided cancer treatment against prior or planned treatment options.
- To evaluate the cost-effectiveness of CMI-guided treatment in correlation with patient outcome results, specifically overall survival.
Main Methods:
- Retrospective analysis of treatment decisions from five clinical trials (n=137) before CMI profiling.
- Systematic review of 11 clinical studies (n=385) comparing planned vs. actual CMI-guided treatment costs.
- Comparison of prior treatment costs versus profiling-guided treatment costs.
Main Results:
- Treatment plans were altered in 88% of cases following CMI profiling.
- Actual CMI-guided treatment cost per cycle was £995.
- Planned treatment costs (£979) were comparable to actual CMI-guided costs (£945), and prior treatment costs (£892) were not significantly different from profiling-guided treatments (£850).
Conclusions:
- The cost per cycle for Caris Molecular Intelligence-guided treatment falls within the range of prior or planned treatment costs.
- The additional expense of CMI's multiplatform testing is justified by improved overall survival, indicating cost-effectiveness.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:21Cancer Survival Analysis